Form 4: United Therapeutics Director Nilda Mesa Receives Stock Options and Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Director Nilda Mesa received stock options and restricted stock units as part of an annual non-employee director award from United Therapeutics Corporation.

Summary

  • On July 25, 2024, Nilda Mesa, a director of United Therapeutics Corporation, was granted stock options for 1,440 shares and 590 restricted stock units (RSUs) as part of her annual non-employee director award.
  • The stock options have an exercise price of $336.37 and vest on July 25, 2025, expiring on July 25, 2034.
  • The RSUs also vest on July 25, 2025, and each unit represents the right to receive one share of United Therapeutics Corporation common stock upon vesting.
  • Following these transactions, Mesa directly owns 1,440 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of equity compensation, which is generally viewed positively as it aligns director interests with shareholders. There are no indications of negative news or concerns.

Positives

  • The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing her to contribute to the company's success.
  • The vesting period of one year encourages the director's continued service to the company.

Industry Context

This type of equity compensation is common for directors of publicly traded companies to align their interests with shareholders.

Comparison to Industry Standards

  • Equity compensation for board members is a standard practice across the biotechnology and pharmaceutical industries.
  • Companies like Amgen, Gilead Sciences, and Biogen also provide stock options and restricted stock units to their non-employee directors as part of their compensation packages.
  • The specific value and vesting schedules can vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

  • Shareholders: The equity grants align the director's interests with shareholder value.
  • Employees: The grants are part of the overall compensation structure and contribute to the company's ability to attract and retain talent.

Key Dates

DateDescription
07/25/2024Date of transaction: Grant of stock options and restricted stock units.
07/25/2025Vesting date for both stock options and restricted stock units.
07/25/2034Expiration date for the stock options.
07/26/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.